2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed modelsLisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl research
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2020
Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up
Grilo CM, White MA, Ivezaj V, Gueorguieva R. Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge‐Eating Disorder: 12‐Month Follow‐up. Obesity 2020, 28: 2116-2124. PMID: 32985114, PMCID: PMC7644623, DOI: 10.1002/oby.22975.Peer-Reviewed Original ResearchConceptsBehavioral weight lossStepped careWeight lossWeight loss medicationsRandomized Controlled TrialsSignificant weight lossBinge-eating disorderBinge-eating frequencySignificant time effectBinge Eating DisorderCognitive behavioral therapyRemission rateControlled TrialsTreatment respondersLong-term effectsBehavioral therapyMixed modelsPatientsCareObesitySignificant reductionTreatmentMonthsPosttreatmentDisordersModulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D’Souza D, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology 2020, 45: 990-997. PMID: 32092760, PMCID: PMC7162891, DOI: 10.1038/s41386-020-0644-9.Peer-Reviewed Original ResearchConceptsAntidepressant effectsKetamine administrationRapamycin pretreatmentMontgomery-Åsberg Depression Rating ScaleDouble-blind cross-over designBenefits of ketamineRobust antidepressant effectsKetamine's antidepressant effectsMajor depressive episodeDepression Rating ScaleCross-over designKetamine exertsOral rapamycinRemission rateDepressive episodePlacebo 2Ketamine 0.5Local blockadeDepressed patientsIntravenous administrationTreatment daysDepression relapseDepression severityKetamineRating ScaleRandomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity
Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity. American Psychologist 2020, 75: 204-218. PMID: 32052995, PMCID: PMC7027689, DOI: 10.1037/amp0000534.Peer-Reviewed Original ResearchConceptsStepped-care treatmentCognitive behavioral therapyWeight loss medicationsBinge-eating disorderStepped careRemission rateWeight lossBehavioral weight lossSignificant weight lossBinge-eating frequencySignificant time effectControlled TrialsTreat analysisTreatment respondersMedicationsPlaceboMixed model analysisClinical practiceNonrespondersPatientsObesityBinge eatingCareMonthsTreatment
2017
A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings
Tolin DF, McGrath PB, Hale LR, Weiner DN, Gueorguieva R. A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings. Applied Psychophysiology And Biofeedback 2017, 42: 51-58. PMID: 28194546, PMCID: PMC5344940, DOI: 10.1007/s10484-017-9354-4.Peer-Reviewed Original ResearchConceptsPanic disorderRespiratory interventionsTreatment settingsTreatment of PDGlobal illness severityTreat response rateNaturalistic treatment settingEnd-tidal CO2Normocapnic rangeRemission rateIllness severityPresent studyClinical resultsFunctional impairmentRepresentative patientsResponse rateClinical settingSimilar outcomesHypocapnic rangeSimilar decreasePanic severityInterventionHome useCliniciansClient adherence
2013
A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression
Hantsoo L, Ward-O’Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 2013, 231: 939-948. PMID: 24173623, PMCID: PMC3945214, DOI: 10.1007/s00213-013-3316-1.Peer-Reviewed Original ResearchConceptsDSM-IV criteriaDouble-blind placebo-controlled trialSelective serotonin reuptake inhibitor sertralineSerotonin reuptake inhibitor sertralineClinical Global Impression scoresHamilton Depression Rating ScaleRating ScaleStrict DSM-IV criteriaDouble-blind trialPlacebo-controlled studyPlacebo-controlled trialHamilton Anxiety Rating ScaleMonths of deliverySubset of womenPrimary outcome variableWeeks of childbirthDepression Rating ScaleGlobal Impression scoresGreater response rateMajor depressive disorderOnset of depressionAnxiety Rating ScaleSignificant groupSertraline 50Remission rateSelf-help for binge eating disorder in primary care: A randomized controlled trial with ethnically and racially diverse obese patients
Grilo CM, White MA, Gueorguieva R, Barnes RD, Masheb RM. Self-help for binge eating disorder in primary care: A randomized controlled trial with ethnically and racially diverse obese patients. Behaviour Research And Therapy 2013, 51: 855-861. PMID: 24189569, PMCID: PMC3863907, DOI: 10.1016/j.brat.2013.10.002.Peer-Reviewed Original ResearchConceptsDiverse obese patientsUsual careObese patientsSelf-help CBTPrimary careEating Disorder ExaminationPrimary care interventionsPrimary care settingSelf-help versionFour-month treatmentSelf-help treatmentFront-line interventionCognitive behavioral therapyRemission rateMixed modelsCare interventionsCare settingsPatientsGeneralist settingsBehavioral therapyDisorder ExaminationDisorder psychopathologyWeight lossBingeCare
2011
Cognitive–Behavioral Therapy, Behavioral Weight Loss, and Sequential Treatment for Obese Patients With Binge-Eating Disorder: A Randomized Controlled Trial
Grilo CM, Masheb RM, Wilson GT, Gueorguieva R, White MA. Cognitive–Behavioral Therapy, Behavioral Weight Loss, and Sequential Treatment for Obese Patients With Binge-Eating Disorder: A Randomized Controlled Trial. Journal Of Consulting And Clinical Psychology 2011, 79: 675-685. PMID: 21859185, PMCID: PMC3258572, DOI: 10.1037/a0025049.Peer-Reviewed Original ResearchConceptsPercent BMI lossBehavioral weight lossBinge-eating disorderCognitive behavioral therapyBMI lossObese patientsWeight lossBinge-eating remissionAlternative treatment optionBinge Eating DisorderRemission rateControlled TrialsTreatment optionsMixed model analysisBehavioral therapyPatientsManualized treatmentAssessment pointsBingeRemissionGreater reductionTreatmentTherapySequential treatmentDisorders